Spots Global Cancer Trial Database for primary breast cancer

Every month we try and update this database with for primary breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)	NCT04127019	Primary Breast ...	Paclitaxel Docetaxel Cyclophosphamid... Epirubicin 5-fluorouracil	18 Years - 75 Years	Fudan University
A Window-of-opportunity Study of Pelareorep in Early Breast Cancer	NCT04102618	Breast Cancer	Pelareorep Letrozole Atezolizumab Trastuzumab	18 Years -	Oncolytics Biotech
Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study)	NCT03711877	Primary Breast ...	Scalp cooling s... Cold cap	18 Years - 65 Years	Peking University
Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy	NCT04468113	Primary Breast ...	Tumark® Vision ...	18 Years -	Kliniken Essen-Mitte
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3	NCT04277338	Primary Breast ...	SPECT	18 Years - 80 Years	Tomsk National Research Medical Center of the Russian Academy of Sciences
Group Therapy for Primary Breast Cancer	NCT00220792	Breast Cancer	Brief supportiv...	0 Years -	Stanford University
Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3	NCT05923177	Primary Breast ...	SPECT	18 Years - 80 Years	Tomsk National Research Medical Center of the Russian Academy of Sciences
Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy	NCT04468113	Primary Breast ...	Tumark® Vision ...	18 Years -	Kliniken Essen-Mitte
mULM to Support Breast Cancer Diagnosis and Therapy	NCT05445050	Primary Breast ...	Application and...	18 Years -	RWTH Aachen University
Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel	NCT00527449	Primary Breast ...	Epirubicin, Car...	18 Years -	Klinikum Weissenfels
Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer	NCT00422903	Neoplasms, Brea...	lapatinib letrozole placebo	18 Years - 80 Years	GlaxoSmithKline
Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)	NCT01779479	Primary Breast ...	Cabacitaxel Paclitaxel	18 Years -	German Breast Group
Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy	NCT03270007	Primary Breast ...	Vinorelbine	18 Years - 66 Years	Peking University
Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer	NCT00422903	Neoplasms, Brea...	lapatinib letrozole placebo	18 Years - 80 Years	GlaxoSmithKline
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer	NCT00793377	Primary Breast ...	Adriamycin (Dox... Adriamycin (Dox...	18 Years -	German Breast Group
Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel	NCT00527449	Primary Breast ...	Epirubicin, Car...	18 Years -	Klinikum Weissenfels
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression	NCT00944047	Breast Cancer	nab-paclitaxel trastuzumab Doxorubicin cyclophosphamid... Growth Factor S... Surgery	18 Years -	University of Kansas Medical Center
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3	NCT04277338	Primary Breast ...	SPECT	18 Years - 80 Years	Tomsk National Research Medical Center of the Russian Academy of Sciences
European Celecoxib Trial in Primary Breast Cancer	NCT02429427	Breast Cancer	Celecoxib Placebo	18 Years -	Imperial College London
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer	NCT01049425	Primary Breast ... Her2 Non-overex...	Epirubicin Cyclophosphamid... Docetaxel Cyclophosphamid... Docetaxel	18 Years - 75 Years	West German Study Group
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3	NCT04277338	Primary Breast ...	SPECT	18 Years - 80 Years	Tomsk National Research Medical Center of the Russian Academy of Sciences
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer	NCT01049425	Primary Breast ... Her2 Non-overex...	Epirubicin Cyclophosphamid... Docetaxel Cyclophosphamid... Docetaxel	18 Years - 75 Years	West German Study Group
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer	NCT01049425	Primary Breast ... Her2 Non-overex...	Epirubicin Cyclophosphamid... Docetaxel Cyclophosphamid... Docetaxel	18 Years - 75 Years	West German Study Group
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer	NCT04109066	Breast Cancer	nivolumab paclitaxel (PTX... nivolumab place... anthracycline cyclophosphamid... Endocrine Thera... Surgery	18 Years -	Bristol-Myers Squibb
Effectiveness of the CHESS eHealth Cancer Support Intervention in Population-based Care	NCT01033162	Primary Breast ...	Enhanced ICCS w...	18 Years -	University of Wisconsin, Madison
TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen	NCT02053597	Breast Cancer	Doxorubicin paclitaxel	18 Years - 40 Years	Jules Bordet Institute

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: